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RUNX1 and breast cancer
Jose Mercado-Matos, Asia N. Matthew-Onabanjo and Leslie M. Shaw
News on: Runx1 stabilizes the mammary epithelial cell phenotype and prevents epithelial to mesenchymal transition by Hong et 
al. Oncotarget. 2017; 8:17610-27. doi: 10.18632/oncotarget.15381
RUNX1 is a member of the RUNX family of 
transcription factors that also includes RUNX2 and 
RUNX3 [1]. Early studies identified RUNX1 as a key 
regulator of definitive hematopoiesis and the role of 
RUNX1 as a tumor suppressor in leukemia is well 
established [1]. In more recent sequencing studies of 
solid tumors, molecular alterations have been identified 
in other cancer types, suggesting a broader role for 
RUNX1 in epithelial cells and carcinomas. RUNX1 is 
the predominant RUNX protein expressed in the normal 
human breast epithelium and it is the only RUNX family 
member for which somatic mutations have been identified 
in human breast cancer. These mutations are primarily 
loss of function mutations that occur through nonsense, 
frameshift or missense mutations within the Runt DNA-
binding domain [1]. These RUNX1 mutations occur 
almost exclusively in the ER+, luminal subtype of breast 
cancer and indicate a tumor suppressor role for RUNX1 
[2]. In contrast, elevated levels of RUNX1 expression 
correlate with poor outcomes in triple negative breast 
cancers (TNBCs), indicating a positive, oncogenic role for 
RUNX1 in this breast cancer subtype [3]. These disparate 
findings support a cell-context dependent role for RUNX1 
in breast cancer.
The functional consequences of RUNX1 loss or gain 
of expression that contribute to breast cancer development 
and progression have not been fully elucidated. A role 
for RUNX1 in suppressing ER oncogenic signaling 
is suggested by the fact that combined loss of Runx1 
with either TP53 or Rb1 leads to hyperproliferation of 
ER+ luminal cells in the mouse mammary gland [2]. 
Inactivating mutations of RUNX1 may be an early event 
that enhances estrogen signaling, creating a permissive 
environment for the development of ER+ luminal tumors. 
Regulation of ER signaling would explain the luminal 
subtype specificity of RUNX1 mutations in human 
breast cancer. With regard to tumor progression, the 
first evidence to support an association of RUNX1 with 
cancer metastasis came from a gene expression analysis 
comparing human primary adenocarcinomas of multiple 
types with unmatched metastatic lesions [4]. A 17-gene 
expression signature that distinguished primary from 
metastatic adenocarcinomas, and that identified primary 
tumors that were most likely to be associated with 
metastasis and poor clinical outcomes, included RUNX1 
(downregulated expression). A recent study by Hong et 
al provides a mechanistic explanation for this association 
of RUNX1 loss with tumor progression to metastasis [5]. 
Specifically, TGF-β downregulates RUNX1 mRNA and 
protein expression in the normal, immortalized mammary 
epithelial cell line, MCF-10A, and loss of RUNX1 is 
required for the ability of TGF-β to induce an epithelial 
mesenchymal transition (EMT) in these cells. Importantly, 
loss of RUNX1 expression alone promotes EMT, which is 
also observed for ER+, luminal MCF-7 cells, indicating 
a direct role for RUNX1 in maintaining the epithelial 
phenotype. One mechanism by which RUNX1 inhibits 
EMT is through interactions with the CDH1 promoter to 
positively regulate E-Cadherin expression. 
In apparent conflict with the role of RUNX1 
as a suppressor of EMT in ER+ luminal tumors, 
downregulation of RUNX1 expression in TN tumors 
inhibits tumor invasion and metastasis [6]. How do both 
high and low levels of RUNX1 expression contribute 
to tumor progression? Although loss of E-Cadherin is 
commonly associated with the mesenchymal, invasive 
phenotype that occurs with EMT, tumor cells can also rely 
upon E-Cadherin expression for collective invasion from 
the tumor [7]. Moreover, in a recent study investigating 
the role of cancer associated fibroblasts (CAFs) in tumor 
invasion, a heterotypic interaction between N-Cadherin 
on CAFs and E-Cadherin on tumor cells was required 
for efficient invasion of squamous cell carcinoma (SCC) 
cells [8]. Therefore, either high or low levels of RUNX1 
could regulate invasion and promote tumor progression in 
breast cancer through a mechanism involving regulation of 
E-Cadherin expression.
In summary, increasing evidence supports a role for 
RUNX1 in breast cancer progression. Understanding how 
RUNX1 functions in a cell context-dependent manner will 
be essential for determining the mechanism(s) by which 
this transcription factor impacts tumor biology.
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